FDA approves test for molecular residual disease monitoring in patients with solid tumors
LawrenceCancer

The U.S. Food and Drug Administration (FDA) has approved a diagnostic test for molecular residual disease (MRD) monitoring in patients with solid tumors. Reported in Cancer, this regulatory outcome introduces an approved diagnostic modality for evaluating disease persistence and monitoring residual tumor burden in solid tumor management.
Key Takeaways
- The FDA has approved a molecular residual disease monitoring test for clinical use in patients with solid tumors.
Read the original sourceCancer
